Evommune signs $1.1bn licence deal with Hinova for EVO570
Evommune will pay $30m upfront, consisting of $20m in cash and $10m in pre-funded warrants for common shares.
Accelerate decision-making with data-led confidence
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity
Australia starts investigation into OpenAI Medicare breach
How DFE Pharma supports confident continuous manufacturing decisions
Industry partnership will determine the success of the transition to low-GWP pMDIs